Alpine Immune Sciences (ALPN) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 2 Phase 2[2], 2 Phase 1[3].
Trial NCT06564142[5] evaluates Povetacicept in Immunoglobulin A Nephropathy with a target enrollment of 605 participants.
No Form 4 insider filings for ALPN were recorded at the SEC in the past 30 days[6].